Medicare Enrolled
Dr. Atul Agarwala, MD
Ophthalmology · Irvington, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Agarwala from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Agarwala?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Agarwala
Dr. Atul Agarwala is an ophthalmology specialist in Irvington, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Agarwala performed 2,218 Medicare services across 1,553 unique beneficiaries.
Between the years covered by Open Payments, Dr. Agarwala received a total of $2,507 from 27 pharmaceutical and/or device companies across 136 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Agarwala is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ 2,218 Medicare services
$2,507 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,218
Medicare services
Bottom 49% in NJ for ophthalmology
1,553
Unique beneficiaries
$82
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~117 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Ultrasound of eye tissue and structures A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures. |
335 | $40 | $150 |
| Extended eye exam with retinal drawing A detailed examination of the back of the eye that includes creating a drawing of the retina. |
270 | $21 | $35 |
| Eye exam, established patient, focused A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom. |
260 | $79 | $125 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
212 | $1 | $2 |
| Retinal photography (fundus photo) This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures. |
121 | $29 | $88 |
| COVID-19 immunoassay detection test A laboratory test that uses an immunoassay method to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) through direct visual observation. |
112 | $41 | $65 |
| Eye injection for retinal disease A procedure involving the administration of medication directly into the eye. |
107 | $98 | $300 |
| Retinal angiography with dye injection This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body. |
105 | $118 | $175 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
99 | $45 | $75 |
| Fluorescein angiography of the eye An imaging test of the front part of the eye using a special camera after a dye is injected to visualize blood flow. |
95 | $133 | $250 |
| Visual field test, extended A test that maps your complete field of vision to detect blind spots or peripheral vision loss. Extended testing provides a more detailed assessment than a standard visual field exam. |
61 | $53 | $101 |
| Retinal imaging (OCT scan) This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye. |
56 | $34 | $75 |
| Bevacizumab injection, 10 mg Administration of a 10 mg dose of bevacizumab medication via injection. |
54 | $56 | $150 |
| Laser repair to improve eye fluid flow A laser procedure used to enhance the drainage of fluid within the eye. |
45 | $215 | $450 |
| Retinal laser destruction of growth A laser procedure used to destroy abnormal growths in the retina. |
43 | $449 | $1,000 |
| Slit lamp examination of the eye This procedure uses a specialized microscope to examine the front portion of the eye. |
41 | $31 | $150 |
| Neuropsychological test evaluation, first hour A professional assessment of cognitive and behavioral functioning using standardized tests. This service covers the initial hour of the evaluation process. |
39 | $84 | $250 |
| Optic nerve imaging (OCT scan) Imaging of the optic nerve. |
34 | $29 | $70 |
| Laser iridotomy for eye fluid drainage A laser procedure creates an opening in the iris to allow fluid to drain from the eye. |
29 | $420 | $800 |
| Amniotic membrane placement on eye surface This procedure involves placing amniotic membrane on the surface of the eye to promote wound healing. |
25 | $1,248 | $2,000 |
| Tear duct plug insertion A procedure to insert a small plug into the tear duct opening to help retain tears on the eye surface. |
18 | $198 | $483 |
| Destruction of eyelid margin growth, 1.0 cm or less This procedure involves the removal or destruction of a growth located on the margin of the eyelid that measures 1.0 centimeter or smaller. |
16 | $198 | $350 |
| Eye drainage system examination An examination of the internal drainage system of the eye to assess how fluid flows and drains from the eye. |
16 | $25 | $55 |
| Imaging of front third of eye Imaging of the front third of the eye. |
13 | $24 | $50 |
| Ultrasound scan to determine eye length and lens power An ultrasound procedure used to measure the length of the eye and calculate the power of the lens. |
12 | $61 | $125 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$2,507
Total received (2018-2024)
Avg $358/year across 7 years
Top 33% in NJ for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
27
Companies
136
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,434 (97.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$74 (2.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$821
2023
$546
2022
$531
2021
$136
2020
$69
2019
$180
2018
$223
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Glaukos Corporation
$372
Alcon Vision LLC
$145
Dompe US, Inc.
$65
Xeris Pharmaceuticals, Inc.
$61
Oyster Point Pharma, Inc.
$49
Mallinckrodt Hospital Products Inc.
$47
Tarsus Pharmaceuticals, Inc.
$30
Boston Scientific Corporation
$23
Bausch & Lomb Americas Inc.
$16
ABBVIE INC.
$14
Top 3 companies account for 70.8% of 2024 payments
All-time payments by company (2018-2024) ›
Glaukos Corporation
$473
Mallinckrodt Hospital Products Inc.
$329
Novartis Pharmaceuticals Corporation
$198
Alcon Vision LLC
$188
Bausch & Lomb Americas Inc.
$148
Sun Pharmaceutical Industries Inc.
$140
Dompe US, Inc.
$136
Bausch & Lomb, a division of Bausch Health US, LLC
$129
GLAUKOS CORPORATION
$99
Oyster Point Pharma, Inc.
$98
Xeris Pharmaceuticals, Inc.
$80
Genentech USA, Inc.
$74
Mallinckrodt LLC
$68
Boston Scientific Corporation
$44
Mallinckrodt Enterprises LLC
$42
Shire North American Group Inc
$40
Kala Pharmaceuticals, Inc.
$30
Tarsus Pharmaceuticals, Inc.
$30
BOSTON SCIENTIFIC CORPORATION
$26
Sight Sciences, Inc.
$25
BIOTISSUE HOLDINGS, INC.
$22
ANI Pharmaceuticals, Inc.
$19
EYEVANCE PHARMACEUTICALS LLC
$15
ABBVIE INC.
$14
AbbVie Inc.
$14
Allergan, Inc.
$14
Allergan Inc.
$13
Top 3 companies account for 39.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ALREX · BESIVANCE · Cequa · EYSUVIS · GVOKE HYPOPEN · IACCESS · INVELTYS · LOTEMAX · LUMIGAN · MIEBO · OXERVATE · PROKERA · PURIFIED CORTROPHIN GEL · RESTASIS · Rocklatan · SYNERGY · Simbrinza · TEARCARE SYSTEM · TRAVATAN Z · TYRVAYA · TobraDex ST · VABYSMO · VYZULTA · WATCHMAN · WATCHMAN FLX · XDEMVY · XIIDRA · XIPERE · iDose · iSTENT iNJECT TRABECULAR MICRO-BYPASS STENT SYSTEM · iStent inject Trabecular Micro-Bypass System Model G2-M-IS
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Ophthalmologists within 10 mi
1,217
Per 100K population
142.5
County median income
$76,712
Nearest hospital
NEWARK BETH ISRAEL MEDICAL CENTER
1.4 mi
1.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Agarwala is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Agarwala experienced with ultrasound of eye tissue and structures?
Based on Medicare claims data, Dr. Agarwala performed 335 ultrasound of eye tissue and structures services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Agarwala receive payments from pharmaceutical companies?
Yes. Dr. Agarwala received a total of $2,507 from 27 companies across 136 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Agarwala's costs compare to other ophthalmologists in Irvington?
Dr. Agarwala's average Medicare payment per service is $82. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Agarwala) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Ophthalmologists in Irvington
Browse ophthalmologists in Irvington ranked by procedure volume and transparency data.
Highest volume
Top Ophthalmologists in NJ
Ophthalmologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Ophthalmologists in NJ
Which NJ ophthalmologists receive the most from drug and device companies.
By company
Glaukos Corporation Payments to Doctors
See all physicians who received payments from Glaukos Corporation.
By company
Mallinckrodt Hospital Products Inc. Payments to Doctors
See all physicians who received payments from Mallinckrodt Hospital Products Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology